Welcome to this Severe Asthma CME Snapshot ™ video series. Each 15-minute module offers focused, clinically actionable education for pulmonologists, clinical immunologists, and other clinicians who manage patients with severe asthma. For a comprehensive curriculum that provides a practical set of recommendations to improve daily functioning and quality of life among patients with severe asthma, clinician learners can complete all 4 modules for a full hour of AMA PRA Category 1 Credit ™.
Ramp up today on the latest information in field of pediatrics with Elsevier's Office of Continuing Medical Education free activities.
This webcast is based on a roundtable discussion on the optimal diagnosis and future management of lysosomal diseases. Three experts specializing in Fabry, Gaucher, and Pompe disease will raise key clinical questions and discuss how to overcome barriers in daily clinical practice across the lysosomal disease spectrum. The experts will provide an update on the long-term effects of ERT and highlight the remaining challenges, including the consequences of delayed diagnosis. They will discuss the role and importance of early diagnosis and treatment initiation, and provide perspectives on the recent advances in screening programs for newborn and high-risk populations. Lastly, the experts will address the position of emerging therapies and strategies for the optimal management of lysosomal diseases.
Welcome to Progress in Spinal Muscular Atrophy (SMA) Management, an Elsevier Learning Center. This learning center is a freely accessible platform that aims to increase clinical knowledge by providing Continuing Medical Education (CME) activities, research articles, and resources for health care professionals (HCPs) who treat patients with spinal muscular atrophy (SMA).
ADVANCING THE CARE OF SEVERE ASTHMA: Differential Diagnosis, Multidisciplinary Management, and Patient EngagementFormat: Webcast Series
Welcome to this Severe Asthma CME Snapshot ™ video series. Each 15-minute module offers focused, clinically actionable education for primary care providers and other clinicians who manage patients with severe asthma. For a comprehensive curriculum that provides a practical set of recommendations on improving daily functioning and quality of life among patients with severe asthma, clinician learners can complete all 4 modules for a full hour of AMA PRA Category 1 Credit ™.
An Update on Emerging Therapies for Cystic Fibrosis and Their Implications for Clinical Outcomes: Independent CME Conference Highlights from the 2018 European Cystic Fibrosis Society (ECFS) ConferenceFormat: Webcast
With the rapid progress in the field of cystic fibrosis (CF), healthcare providers are continuously challenged to keep abreast of the latest data in the treatment and management of CF to achieve optimal care of people with CF. This activity provides analyses and clinical perspectives of new and emerging clinical trials data on CFTR modulators presented at the 2018 European Cystic Fibrosis Society (ECFS) Conference*. International expert faculty will examine these latest data, deliberate on the challenges associated with the evaluation of new agents, and discuss the implications of these data for people with CF.
*This webcast is not endorsed by the conference organizer. Elsevier Office of Continuing Medical Education is an independent medical education company that provides clinical updates, analysis, and expert perspectives through conference-coverage educational programs.
This activity is presented as a roundtable discussion between three international expert faculty in cystic fibrosis (CF). This expert faculty will discuss the role of aerosolized agents for improving airway clearance, including caveats from their own extensive clinical experience in managing patients with this condition. The faculty will also deliberate on strategies to improve patient adherence to CF therapy in a case study based format. These discussions will support participants in clinical decision making as well as in helping their patients achieve optimal benefit through adherence to their CF therapy.
THE EMERGING ROLE OF CFTR COMBINATION REGIMENS IN IMPROVING OUTCOMES FOR PATIENTS WITH CYSTIC FIBROSISFormat: Webcast
The content for this activity is based on the live, inter professional seminar titled, “The Emerging Role of CFTR Combination Regimens in Improving Outcomes for Patients With Cystic Fibrosis” that was presented at the 31st Annual North American Cystic Fibrosis Conference in Indianapolis, Indiana. This CME/CNE activity will highlight the latest advances in CFTR-based therapeutics for the treatment of patients with cystic fibrosis. The expert faculty will utilize an interactive panel format to present and discuss recent trial data as it relates to clinical decision-making, including updates regarding the assessment, monitoring, and management of patients treated with CFTR modulated therapies. This educational activity is intended to increase the knowledge and competencies of the multidisciplinary team involved in the care of the CF patient population. Upon completion of this educational activity, the healthcare team will be better equipped with vital information for improving outcomes and quality of life in patients with cystic fibrosis.
This webcast was recorded during a live symposium at the American Society of Human Genetics (ASHG) Annual Meeting in Orlando, FL, USA, on October 19, 2017. During the symposium, the faculty of leading KOLs in the field provided an overview of the clinical picture of Fabry disease and its natural history. They offered guidance on identifying the correlation between genotype and phenotype and how this may affect disease progression. They also discussed the current need for individualized patient care, and reviewed the emerging treatment landscape on the basis of the latest scientific data. They used interactive plenary sessions and selected patient case presentations to encourage the exchange of views and opinions on diagnosing and treating this disease.
The 71st American Epilepsy Society (AES) Annual Meeting was held in Washington, DC, December 1-5, 2017. The conference attracts clinicians, scientists investigating basic and clinical aspects of epilepsy, and other professionals interested in seizure disorders. In this activity, 2 experts summarize the key learnings from this year’s conference focusing on seizure disorders.
Dravet syndrome (DS), a rare form of epilepsy, occurs in approximately 1 in 20,000 live births and is associated with a significant humanistic and economic burden on caregivers, families, and patients. While many medications are used in treating the seizures associated with DS, there are currently no FDA-approved treatments, and nearly all patients continue to have uncontrolled seizures and other medical needs throughout their lifetime. Several investigational therapies are in late-stage development with the potential to provide new treatment options to address the serious medical needs for patients with DS.
This webcast is based on a discussion between two leading experts in the field of spinal muscular atrophy (SMA) who exchange views on “The 2017 Update of the Standard of Care Recommendations for SMA”. They summarize and review the current best practices for diagnosis, multidisciplinary care, physical therapy, orthopedic care, nutrition, pulmonary care, and acute care and discuss how novel treatment options such as newly approved medications have impacted the outlook for patients and are changing the care setting. The experts provide an outlook on how developments such as newborn screening will influence the future of SMA management.
This webcast was recorded during a live symposium at the WORLDSymposium Meeting in San Diego, CA, USA, on February 7, 2018. During the symposium, experts from around the world discussed the key clinical questions and controversies in the diagnosis of Fabry disease and the future direction of clinical management. They also addressed the consequences of delayed diagnosis and treatment initiation, provided guidance on understanding available diagnostic options, and discussed genotype–phenotype correlations and their significance for daily clinical practice.
During this web-based Clinical Issues™ program, a panel of expert faculty will discuss and debate a series of topics related to comprehensively evaluating and longitudinally managing patients with severe asthma, including how the evolving evidence base should shape clinical decision-making and implications of new study data presented at the 2018 American Thoracic Society International Conference.
How Gene Replacement Therapy is Changing the Way We Manage Spinal Muscular Atrophy and Other Neurologic DiseasesFormat: Supplement
Innovations in technology, delivery, and vector systems in gene therapy mean that patients with potentially devastating neuromuscular disorders, such as spinal muscular atrophy (SMA), are now candidates for treatment. As these therapies emerge, clinicians need to understand how they work and associated broader implications for disease management. This supplement reviews the mechanisms by which viral vector systems correct gene defects and corresponding protein deficits, and discusses findings from recent and ongoing clinical trials. In addition, the authors—all experts in SMA—provide commentary on related topics and respond to frequently asked questions about SMA and gene replacement therapy.